Bristol-Myers Squibb Company (BMY)
| Market Cap | 113.30B |
| Revenue (ttm) | 48.30B |
| Net Income (ttm) | -8.95B |
| Shares Out | 2.03B |
| EPS (ttm) | -4.41 |
| PE Ratio | n/a |
| Forward PE | 8.26 |
| Dividend | $2.48 (4.44%) |
| Ex-Dividend Date | Jan 3, 2025 |
| Volume | 8,044,007 |
| Open | 55.43 |
| Previous Close | 55.79 |
| Day's Range | 54.85 - 56.06 |
| 52-Week Range | 39.35 - 61.10 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 58.00 (+3.89%) |
| Earnings Date | Feb 6, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $58.0, which is an increase of 3.89% from the latest price.
News
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise is B...
BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
STOCKHOLM , Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from th...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant.
Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis.
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial.
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb & Co BMY released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions. Despite a rece...
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma.
Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and concerns over patent expirations for key drugs. CEO Chris Boerner's multiyear plan focus...
Trade Tracker: Josh Brown sells Bristol Myers after buying it on Monday
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Bristol Myers so quickly.
Bristol-Myers Squibb Company (BMY) Q4 2024 Earnings Conference Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY) Q4 2024 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Boar...
Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Thursday.
Cramer's Mad Dash: Bristol Myers
CNBC's Jim Cramer breaks down why he's keeping an eye on shares of Bristol Myers.
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
On Thursday, Bristol Myers Squibb & Co BMY posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 billion.
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to chart a path toward long-term growth. The company also issued a full-year ...
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024.
Trade Tracker: Josh Brown buys Bristol-Myers
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's buying Bristol-Myers at these levels.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program are key focus areas for potential healthcare reforms.
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Opdivo plus Yervoy as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced HCC.
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma.
10 Undervalued Dividend Growth Stocks: January 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, an...
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS Presents Results from CheckMate -8HW.